Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Christopher M. Reynolds"'
Autor:
William R. Macon, Thomas M. Habermann, Jonathon B. Cohen, Jonathan W. Friedberg, Nadia Khan, Richard F. Little, Fangxin Hong, Christopher M. Reynolds, Lale Kostakoglu, Rebecca L. King, Thomas E. Witzig, Brad S. Kahl, Gauri G. Nagargoje, Jennifer E Amengual, David Scott, John P. Leonard, Grzegorz S. Nowakowski, Nina D. Wagner-Johnston, James L. Wade, Carla Casulo, Kristy L. Richards
Publikováno v:
Journal of Clinical Oncology. 39:1329-1338
PURPOSE Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell–lik
Publikováno v:
Nanotechnology, Science and Applications, Vol 2010, Iss default, Pp 53-63 (2010)
Robert K DeLong1, Christopher M Reynolds1, Yaneika Malcolm1, Ashley Schaeffer1, Tiffany Severs2, Adam Wanekaya21Department of Biomedical Science (Cell and Molecular Biology Program), 2Department of Chemistry, Missouri State University, Springfield, M
Externí odkaz:
https://doaj.org/article/3b0bcf9de0ff4e4e8350c35b7b12e9a5
Autor:
Funda Meric-Bernstam, Michael Rothe, Elizabeth Garrett-Mayer, Rodolfo Gutierrez, Eugene R Ahn, Timothy Lewis Cannon, Steven Francis Powell, John C. Krauss, Christopher M. Reynolds, Margaret von Mehren, Deepti Behl, Carmen Julia Calfa, Herbert Leon Duvivier, Henry G. Kaplan, Michael B. Livingston, Manish Sharma, Walter John Urba, Raegan O'Lone, Susan Halabi, Richard L. Schilsky
Publikováno v:
Journal of Clinical Oncology. 40:3008-3008
3008 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with solid tumors with BRAF V600E/D/K/R mutat
Autor:
Stephen P. Kahanic, Brian G.M. Durie, Joshua Epstein, Muneer H. Abidi, Rachael Sexton, Bart Barlogie, Antje Hoering, Mohan C. Thakuri, Robert Z. Orlowski, Christopher M. Reynolds, S. Vincent Rajkumar, Frederic J. Reu, Angela Dispenzieri
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 5, Pp 1-11 (2020)
Blood Cancer Journal
Blood Cancer Journal
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable pa
Autor:
Angela Dispenzieri, Stephen P. Kahanic, Rachael Sexton, S. Vincent Rajkumar, Frederic J. Reu, Brian G.M. Durie, Christopher M. Reynolds, Bart Barlogie, Robert Z. Orlowski, Muneer H. Abidi, Joshua Epstein, Mohan C. Thakuri, Antje Hoering
Publikováno v:
The Lancet. 389:519-527
Summary Background Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the se
Autor:
Christina M Walter, Kathleen Goren, Dana R. Epstein, Nicole Hoffmann, Mary Lu Bushnell, Nicole A. Roberts, Christopher M Reynolds, Katrina Powell, Lori B Burmeister, Mary H. Burleson, Michael J. Todd
Publikováno v:
Psychological services. 17(1)
This study investigated the feasibility and preliminary effectiveness of a pilot program designed to address subjective memory complaints among Veterans. The program, Brain Boosters, consisted of 10 once-weekly group sessions, during which psychoeduc
Autor:
Opeyemi Jegede, Priyank P Patel, N. Nora Bennani, Craig A. Portell, Seema Naik, Christopher M. Reynolds, Brad S. Kahl, Benjamin M. Parsons
Publikováno v:
Blood. 134:5243-5243
Background: Mantle Cell Lymphoma (MCL) is an aggressive form of Non Hodgkin Lymphoma (NHL) and typically presents in patients over the age of 60 years. Bendamustine and rituximab (BR) combination is one of the standard treatments for MCL and is given
Autor:
Edward S. Kim, Christopher M. Reynolds, Karen Kelly, Roy S. Herbst, James Moon, Fred R. Hirsch, Mary W. Redman, David R. Gandara, Perry Guaglianone, Kurt R. Oettel, Gregory A. Masters, Lyudmila Bazhenova, Marileila Varella-Garcia, Thomas J. Semrad, Philip C. Mack, Charles D. Blanke, Susanne M. Arnold, Anand B. Karnad
Publikováno v:
The Lancet. Oncology, vol 19, iss 1
Herbst, RS; Redman, MW; Kim, ES; Semrad, TJ; Bazhenova, L; Masters, G; et al.(2018). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet Oncology, 19(1), 101-114. doi: 10.1016/S1470-2045(17)30694-0. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/6nq1g8m1
Herbst, RS; Redman, MW; Kim, ES; Semrad, TJ; Bazhenova, L; Masters, G; et al.(2018). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet Oncology, 19(1), 101-114. doi: 10.1016/S1470-2045(17)30694-0. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/6nq1g8m1
© 2018 Elsevier Ltd Background EGFR antibodies have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that EGFR copy number by fluorescence in-situ hybridisation (F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d0acfb7ec92cc199bc79d2b6157791
https://escholarship.org/uc/item/6nq1g8m1
https://escholarship.org/uc/item/6nq1g8m1
Autor:
Brad S. Kahl, Thomas M. Habermann, G.G. Nagargoje, Kristy L. Richards, Christopher M. Reynolds, James L. Wade, Nadia Khan, G.S. Nowakowski, Carla Casulo, L. Kostakoglu, Richard F. Little, Jonathan W. Friedberg, Jonathon B. Cohen, T. E. Witzig, David Scott, John P. Leonard, Jennifer E Amengual, Rebecca L. King, Fangxin Hong, Nina D. Wagner-Johnston, R. Macon
Publikováno v:
Hematological Oncology. 37:37-38
Autor:
Mohan C. Thakuri, Joshua Epstein, Muneer H. Abidi, Stephen P. Kahanic, Angela Dispenzieri, S. Vincent Rajkumar, Robert Z. Orlowski, Rachael Sexton, Frederic J. Reu, Christopher M. Reynolds, Bart Barlogie, Antje Hoering, Brian G.M. Durie
Publikováno v:
Blood. 132:1992-1992
Background: SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). The primary end point was progression-free survival (PFS) using a pre-specified one-sided strati